Intas Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 175.47 Cr
- Paid Up Capital ₹ 114.77 Cr
- Company Age 39 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 754.50 Cr
- Satisfied Charges ₹ 7,174.94 Cr
- Revenue Growth -3.44%
- Profit Growth -17.74%
- Ebitda -18.86%
- Net Worth 13.06%
- Total Assets 8.17%
About Intas Pharmaceuticals
Intas Pharmaceuticals Limited (IPL) is a leading Public Limited Indian Non-Government Company incorporated in India on 31 May 1985 and has a history of 39 years and eight months. Its registered office is in Ahmedabad, Gujarat, India.
The Corporate was formerly known as Intas Laboratories Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 175.47 Cr and a paid-up capital of Rs 114.77 Cr.
The company currently has active open charges totaling ₹754.50 Cr. The company has closed loans amounting to ₹7,174.94 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Intas Pharmaceuticals Limited India are Manoj Nair as COMPANY SECRETARY and Jayesh Shah as Cfo. Archana Dholakia, Venkatesh Ratnasami, John Goddard, and Eight other members serve as directors at the Company.
Company Details
-
Location
Ahmedabad, Gujarat, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U24231GJ1985PLC007866
-
Company No.
007866
-
Company Classification
Public Limited Indian Non-Government Company
-
Incorporation Date
31 May 1985
-
Date of AGM
31 Jul 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Ahmedabad
Industry
What products or services does Intas Pharmaceuticals Limited offer?
Intas Pharmaceuticals Limited offers a wide range of products and services, including Hair Care, Hair Growth for Men, Specialty Supplements, Probiotics, Skin Care, Facewash, Vitamins & Supplements, Vitamins A-Z, Health Conditions, Kidney Care.
Who are the key members and board of directors at Intas Pharmaceuticals?
Executive Team (5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Manoj Nair
|
Company Secretary | 08-Jun-2007 | Current |
|
Jayesh Shah
|
CFO | 21-Mar-2023 | Current |
|
Nimish Chudgar
|
Managing Director | 31-May-1985 | Current |
|
Binish Chudgar
|
Managing Director | 31-May-1985 | Current |
|
Urmish Chudgar
|
Managing Director | 30-Sep-1996 | Current |
Board Members (8)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
John Goddard
|
Director | 09-Feb-2011 | Current |
|
Archana Dholakia
|
Director | 14-Jun-2023 | Current |
|
Venkatesh Ratnasami
|
Nominee Director | 13-Nov-2014 | Current |
|
Jayesh Shah
|
Cfo and Whole-Time Director | 21-Mar-2018 | Current |
|
Tilokchand Ostwal
|
Director | 19-Mar-2011 | Current |
|
Surender Kumar
|
Director | 09-Feb-2011 | Current |
Financial Performance of Intas Pharmaceuticals.
Intas Pharmaceuticals Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 3.44% decrease. The company also saw a substantial fall in profitability, with a 17.74% decrease in profit. The company's net worth Soared by an impressive increase of 13.06%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Intas Pharmaceuticals?
In 2023, Intas Pharmaceuticals had a promoter holding of 83.84% and a public holding of 16.16%. The company had 1 Subsidiary. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Tfs Business Advisors India Private LimitedSurender Kumar is a mutual person
-
One Advertising And Communication Services LimitedJayesh Shah is a mutual person
-
Jina Pharmaceuticals Limited.Binish Chudgar is a mutual person
-
Gebbs Healthcare Solutions Private LimitedSanjay Kukreja is a mutual person
-
Cremica Food Park Private LimitedSurender Kumar is a mutual person
-
Credila Financial Services LimitedSanjay Kukreja is a mutual person
Charges (Loans)
₹754.50 Cr
₹7,174.94 Cr
Charges Breakdown by Lending Institutions
- Others : 750.00 Cr
- Dena Bank : 4.50 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 25 Jun 1999 | Others | ₹750.00 Cr | Open |
| 01 May 1998 | Dena Bank | ₹4.50 Cr | Open |
| 04 Sep 2017 | Standard Chartered Bank | ₹184.62 Cr | Satisfied |
| 28 Dec 2016 | Others | ₹3,218.29 Cr | Satisfied |
| 28 Dec 2016 | Others | ₹1,845.87 Cr | Satisfied |
How Many Employees Work at Intas Pharmaceuticals?
Intas Pharmaceuticals has a workforce of 18317 employees as of Apr 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Intas Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Intas Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
